

9 September 2026

Issue of Options

This notice is given under NZX Listing Rule 3.13.1 and relates to unlisted Options to acquire ordinary shares in the Company ('Options') issued under the Fisher & Paykel Healthcare 2025 Share Option Plan ('Option Plan') and the Fisher & Paykel Healthcare 2025 Share Option Plan – North America ('North America Plan').

Section 1: Issuer information	
Name of issuer	Fisher & Paykel Healthcare Corporation Limited
NZX ticker code	FPH
Class of financial product	Options issued under the Option Plan and the North America Plan.
ISIN (If unknown, check on NZX website)	NZFAPE0001S2
Currency	NZD
Section 2: Capital change details	
Number issued/acquired/redeemed	39,665
Nominal value (if any)	Not applicable
Issue/acquisition/redemption price per security	No amount is payable for the grant of Options. The Options have an exercise price of \$44.41 per share (being the volume weighted average price for a share on the NZX for the five business days prior to the grant date).
Nature of the payment (for example, cash or other consideration)	Not applicable
Amount paid up (if not in full)	Not applicable
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) ¹	39,665 Options to acquire ordinary shares representing approximately 0.0067% of the ordinary shares on issue.
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	Not applicable
Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	Issue of Options under the Option Plan and the North America Plan to incentivise selected employees to grow the Company and to attract, motivate and retain key employees.
Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	Total number of Options on issue as at the date of this notice after the issue disclosed in this notice: 1,616,254
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	Not applicable

¹ The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Directors' resolution dated 25 August 2026.
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	The Options will be issued on the terms of the Option Plan and the North America Plan, as approved by the Board.
Date of issue/acquisition/redemption ²	8 September 2026
Section 3: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Raelene Leonard
Contact person for this announcement	Raelene Leonard
Contact phone number	+64 9 610 4803
Contact email address	Raelene.Leonard@fphcare.co.nz
Date of release through MAP	9 September 2026

² Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).

9 September 2026

Issue of Performance Share Rights

This notice is given under NZX Listing Rule 3.13.1 and relates to unlisted Performance Share Rights to acquire ordinary shares in the Company ('PSRs') issued under the Fisher & Paykel Healthcare 2025 Performance Share Rights Plan ('PSR Plan') and the Fisher & Paykel Healthcare 2025 Performance Share Rights Plan – North America ('North America Plan').

Section 1: Issuer information	
Name of issuer	Fisher & Paykel Healthcare Corporation Limited
NZX ticker code	FPH
Class of financial product	Unlisted PSRs issued under the PSR Plan and the North America Plan.
ISIN (If unknown, check on NZX website)	NZFAPE0001S2
Currency	NZD
Section 2: Capital change details	
Number issued/acquired/redeemed	223,505
Nominal value (if any)	Not applicable
Issue/acquisition/redemption price per security	No amount is payable for the grant of PSRs. One PSR gives the participant the potential to exercise that PSR for one ordinary share at no cost.
Nature of the payment (for example, cash or other consideration)	Not applicable
Amount paid up (if not in full)	Not applicable
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) ¹	223,505 PSRs represent approximately 0.0380% of the ordinary shares on issue.
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	Not applicable
Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	Issue of PSRs under the PSR Plan and the North America Plan to incentivise selected employees to grow the Company and to attract, motivate and retain key employees.
Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	Total number of PSRs on issue as at the date of this notice after the issue disclosed in this notice: 1,087,097
In the case of an acquisition of shares, whether those shares are to be held as treasury stock	Not applicable

¹ The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Directors' resolution dated 25 August 2026.
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	The PSRs will be issued on the terms of the PSR Plan and the North America Plan, as approved by the Board.
Date of issue/acquisition/redemption ²	8 September 2026
Section 3: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Raelene Leonard
Contact person for this announcement	Raelene Leonard
Contact phone number	+64 9 610 4803
Contact email address	Raelene.Leonard@fphcare.co.nz
Date of release through MAP	9 September 2026

² Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).

9 September 2026

Issue of Employee Share Rights

This notice is given under NZX Listing Rule 3.13.1 and relates to unlisted Employee Share Rights to acquire ordinary shares in the Company ('ESRs') issued under the Fisher & Paykel Healthcare Employee Share Rights Plan ('Employee Share Rights Plan'), the Sub-Plan for France ('Sub-Plan for France') and the Fisher & Paykel Healthcare Employee Share Rights Plan – North America ('North America Plan').

Section 1: Issuer information	
Name of issuer	Fisher & Paykel Healthcare Corporation Limited
NZX ticker code	FPH
Class of financial product	Unlisted ESRs to acquire ordinary shares in the Company issued under the Employee Share Rights Plan, the Sub-Plan for France and the North America Plan.
ISIN (If unknown, check on NZX website)	NZFAPE0001S2
Currency	NZD
Section 2: Capital change details	
Number issued/acquired/redeemed	299,018
Nominal value (if any)	Not applicable
Issue/acquisition/redemption price per security	No amount is payable for the grant of ESRs. One ESR will convert into one ordinary share at no cost after three years, provided the recipient remains an employee of the Company.
Nature of the payment (for example, cash or other consideration)	Not applicable
Amount paid up (if not in full)	Not applicable
Percentage of total class of Financial Products issued/acquired/redeemed/ (calculated on the number of Financial Products of the Class, excluding any Treasury Stock, in existence) ¹	299,018 ESRs to acquire ordinary shares representing approximately 0.0508% of the ordinary shares on issue.
For an issue of Convertible Financial Products or Options, the principal terms of Conversion (for example the Conversion price and Conversion date and the ranking of the Financial Product in relation to other Classes of Financial Product) or the Option (for example, the exercise price and exercise date)	Not applicable
Reason for issue/acquisition/redemption and specific authority for issue/acquisition/redemption/ (the reason for change must be identified here)	Issue of ESRs under the Employee Share Rights Plan to incentivise selected employees to grow the Company and to attract, motivate and retain key employees.
Total number of Financial Products of the Class after the issue/acquisition/redemption/Conversion (excluding Treasury Stock) and the total number of Financial Products of the Class held as Treasury Stock after the issue/acquisition/redemption.	Total number of ESRs on issue as at the date of this notice after the issue disclosed in this notice: 886,792

¹ The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.

In the case of an acquisition of shares, whether those shares are to be held as treasury stock	Not applicable
Specific authority for the issue, acquisition, or redemption, including a reference to the rule pursuant to which the issue, acquisition, or redemption is made	Directors' resolution dated 25 August 2026.
Terms or details of the issue, acquisition, or redemption (for example: restrictions, escrow arrangements)	The ESRs will be issued on the terms of the Employee Share Rights Plan, the Sub-Plan for France and the North America Plan, as approved by the Board.
Date of issue/acquisition/redemption ²	8 September 2026
Section 3: Authority for this announcement and contact person	
Name of person authorised to make this announcement	Raelene Leonard
Contact person for this announcement	Raelene Leonard
Contact phone number	+64 9 610 4803
Contact email address	Raelene.Leonard@fphcare.co.nz
Date of release through MAP	9 September 2026

² Continuous issuers using this form in reliance on Rule 3.13.2, please indicate the period during which the relevant issue/acquisition/redemptions were made (for example, 1 January 2019 to 31 January 2019).